
IRON Stock Forecast & Price Target
IRON Analyst Ratings
Bulls say
Disc Medicine is supported by a de-risked, mechanism-driven pipeline that targets major unmet needs in hematologic disease, with bitopertin now showing decisive Phase 3 evidence in EPP/XLP and supporting a path to approval and launch. Its MF-anemia program, selcodebart, has shown a 50% to 64% major hematologic response in interim Phase 2 data where no approved therapy exists, while DISC-3405 adds another differentiated shot on goal in PV with convenient dosing and a potentially meaningful commercial niche. Financially, the company reported a $1.53 loss per share for 3Q, R&D of $44.1M, operating loss of $64.2M, and cash, cash equivalents, and marketable securities of $682.8M, with a public offering adding roughly $485.9M in net proceeds to support operations into 2030.
Bears say
Disc Medicine is exposed to the classic biotech risks of clinical, regulatory, financing, manufacturing, and IP setbacks, but the more important issue is pipeline fragility: bitopertin could face additional NDA delays and, even if approved, may see slower-than-expected uptake in a largely treatment-naïve EPP/XLP population. The bearish case is amplified by selcodebart, where unforeseen safety problems or efficacy falling below a 30% responder rate in MF-anemia would leave it only minimally differentiated versus current options and potentially limit share to about 10% of anemic patients. Competition in PV also looks unfavorable, as better-than-expected Ph 3 results from divesiran or sapablursen could pressure Disc Medicine’s commercial prospects while physicians remain cautious about anemia risk from extended dosing.
This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.
IRON Analyst Forecast & Price Prediction
Start investing in IRON
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Disc Medicine Inc (IRON) Forecast
IRON Analyst Forecast & Price Prediction
Start investing in IRON
Order type
Buy in
Order amount
Est. shares
0 shares